Subcutaneous Infliximab [CT-P13], a True Biologic 2.0. Real Clinical Practice Multicentre Study

Background: Inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, is characterized by chronic relapsing intestinal inflammation. There are few data on the efficacy and safety in clinical practice of infliximab (CT-P13) in subcutaneous formulation (SC) for the treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Huguet, Jose M., García-Lorenzo, Victor, Martí, Lidia, Paredes, Jose María, Ramírez, Jose Joaquin, Pastor, Miguel, Ruiz, Lucia, Sanahuja, Ana, Timoneda, Pilar, Sanchís, Laura, Pérez, Gloria Alemany, Boscá-Watts, Marta Maia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9495964/
https://www.ncbi.nlm.nih.gov/pubmed/36140230
http://dx.doi.org/10.3390/biomedicines10092130

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9495964/
https://www.ncbi.nlm.nih.gov/pubmed/36140230
http://dx.doi.org/10.3390/biomedicines10092130

Ejemplares similares